Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Lyra Therapeutics and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | N/A | N/A | N/A |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Risk & Volatility
Lyra Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Lyra Therapeutics and Aditxt, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
This table compares Lyra Therapeutics and Aditxt”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyra Therapeutics | $400,000.00 | 0.84 | -$28.92 million | ($19.15) | -0.01 |
| Aditxt | $14,336.00 | 0.02 | -$41.71 million | ($100,788.35) | -0.00 |
Lyra Therapeutics has higher revenue and earnings than Aditxt. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Summary
Lyra Therapeutics beats Aditxt on 9 of the 10 factors compared between the two stocks.
About Lyra Therapeutics
Lyra Therapeutics is a biotechnology company focused on developing long-acting, locally administered treatments for diseases of the ear, nose and throat. The company’s programs are designed to deliver medication directly to the nasal passages, with the goal of improving treatment duration, reducing reliance on daily therapies and addressing limitations associated with conventional nasal sprays. Lyra’s technology is based on its proprietary, bioresorbable nasal delivery platform, which is intended to provide controlled drug release over an extended period.
About Aditxt
Aditxt, Inc. (NASDAQ: ADTX) is a biotechnology company focused on developing technologies designed to monitor and improve the human immune system. Its work centers on immune profiling, precision health and personalized medicine, with the goal of helping healthcare providers and researchers better understand individual immune responses. The company’s primary technology platform, AditxtScore, is designed to analyze multiple immune system biomarkers simultaneously. The platform is intended for applications including disease detection, monitoring immune responses to infections and vaccines, and supporting the development of personalized treatment strategies.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
